Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.


Journal Article

Data from the 5 large randomized, double-blind, placebo-controlled trials that used glycoprotein IIb/IIIa inhibitors during percutaneous transluminal coronary angioplasty were pooled for a total of 10,691 patients. We found that the use of glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions significantly decreases the need for unplanned stenting for abrupt closure.

Full Text

Duke Authors

Cited Authors

  • Bhatt, DL; Lincoff, AM; Kereiakes, DJ; Tcheng, JE; Simoons, ML; van der Wieken, LR; Godfrey, N; Califf, RM; Topol, EJ

Published Date

  • November 1, 1998

Published In

Volume / Issue

  • 82 / 9

Start / End Page

  • 1105 - A6

PubMed ID

  • 9817488

Pubmed Central ID

  • 9817488

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/s0002-9149(98)00565-7


  • eng

Conference Location

  • United States